{
  "id": 8897225,
  "title": "Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts",
  "url": "https://urgent.news/2026/09/21/expect-high-tide-of-chinese-biotech-deals-as-threat-of-us-curbs-fades-8897225",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-21T10:00:10.000Z",
  "source": {
    "name": "SCMP Business",
    "slug": "scmp-business",
    "url": "https://www.scmp.com/business/china-business/article/3368249/expect-high-tide-chinese-biotech-deals-threat-us-curbs-fades-analysts"
  },
  "original_language": "en",
  "account": "Analysts predict a surge in Chinese biotech deals as the threat of US restrictions eases, providing a significant boost to Chinese healthcare firms. Jialin Zhang, Nomura's head of China healthcare research, stated that out-licensing deals between China and the US will \"ride on a high tide\" in this favorable environment. The US Treasury Department is reportedly drafting investment rules that would allow American pharmaceutical firms to license most Chinese drugs, provided they do not involve pathogens or weaponisable biotechnology. This softer stance differs from the restrictive measures outlined in two US bills earlier this year. Tony Ren, head of Asia Healthcare Research at Macquarie, emphasized that these developments align with China's ambition to become a global biomedicine powerhouse. The value of out-licensing deals involving China-made innovative drugs has surged by 36% this year, reaching US$120 billion. Despite the prospect of geopolitical volatility ahead of the US midterm elections, the industry's lobbying efforts have evidently paid off, as evidenced by the recent rally in shares of Chinese biotech and pharmaceutical firms listed in Hong Kong.",
  "summary": "US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for the sector. Out-licensing deals between China and the US would “ride on a high tide” in the favourable environment, said Nomura’s head of China healthcare…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "South China Morning Post",
        "title": "Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts",
        "url": "https://urgent.news/2026/09/21/expect-high-tide-of-chinese-biotech-deals-as-threat-of-us-curbs-fades",
        "published": "2026-09-21T10:00:10.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}